Cargando…

Allogeneic mesenchymal stem cell therapy: A regenerative medicine approach to geroscience

Extraordinary advances in medicine and public health have contributed to increasing life expectancy worldwide. However, health span—“healthy aging”—has paradoxically lagged to parallel this increase. Consequently, aging‐associated illnesses, such as Alzheimer's disease and aging frailty, are ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliva, Anthony A., McClain‐Moss, Lisa, Pena, Andrea, Drouillard, Amy, Hare, Joshua M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820701/
https://www.ncbi.nlm.nih.gov/pubmed/31667462
http://dx.doi.org/10.1002/agm2.12079
_version_ 1783463998047387648
author Oliva, Anthony A.
McClain‐Moss, Lisa
Pena, Andrea
Drouillard, Amy
Hare, Joshua M.
author_facet Oliva, Anthony A.
McClain‐Moss, Lisa
Pena, Andrea
Drouillard, Amy
Hare, Joshua M.
author_sort Oliva, Anthony A.
collection PubMed
description Extraordinary advances in medicine and public health have contributed to increasing life expectancy worldwide. However, health span—“healthy aging”—has paradoxically lagged to parallel this increase. Consequently, aging‐associated illnesses, such as Alzheimer's disease and aging frailty, are having a growing impact on patients, their families, and entire health‐care systems. Typically, such disorders have been treated as isolated disease entities. However, the inextricable links between aging‐associated disorders and the aging process itself have become increasingly recognized, leading to formation of the field of geroscience. The geroscience concept is that treating the aging process itself should lead to treatment and prevention of aging‐related disorders. However, the aging process is complex, dictated by highly interrelated pleiotropic processes. As such, therapeutics with pleiotropic mechanisms of action (either alone, or as part of combinatorial strategies) will be required for preventing and treating both aging and related disorders. Mesenchymal stem cells (MSCs) have multiple mechanisms of action that make these highly promising geroscience therapeutic candidates. These cells have a high safety profile for clinical use, are amenable to allogeneic use since tissue‐type matching is not required, and can have sustained activity after transplantation. Herein, we review preclinical and clinical data supporting the utility of allogeneic MSCs as a geroscience therapeutic candidate.
format Online
Article
Text
id pubmed-6820701
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68207012020-01-15 Allogeneic mesenchymal stem cell therapy: A regenerative medicine approach to geroscience Oliva, Anthony A. McClain‐Moss, Lisa Pena, Andrea Drouillard, Amy Hare, Joshua M. Aging Med (Milton) Review Articles Extraordinary advances in medicine and public health have contributed to increasing life expectancy worldwide. However, health span—“healthy aging”—has paradoxically lagged to parallel this increase. Consequently, aging‐associated illnesses, such as Alzheimer's disease and aging frailty, are having a growing impact on patients, their families, and entire health‐care systems. Typically, such disorders have been treated as isolated disease entities. However, the inextricable links between aging‐associated disorders and the aging process itself have become increasingly recognized, leading to formation of the field of geroscience. The geroscience concept is that treating the aging process itself should lead to treatment and prevention of aging‐related disorders. However, the aging process is complex, dictated by highly interrelated pleiotropic processes. As such, therapeutics with pleiotropic mechanisms of action (either alone, or as part of combinatorial strategies) will be required for preventing and treating both aging and related disorders. Mesenchymal stem cells (MSCs) have multiple mechanisms of action that make these highly promising geroscience therapeutic candidates. These cells have a high safety profile for clinical use, are amenable to allogeneic use since tissue‐type matching is not required, and can have sustained activity after transplantation. Herein, we review preclinical and clinical data supporting the utility of allogeneic MSCs as a geroscience therapeutic candidate. John Wiley and Sons Inc. 2019-09-17 /pmc/articles/PMC6820701/ /pubmed/31667462 http://dx.doi.org/10.1002/agm2.12079 Text en © 2019 Longeveron LLC Aging Medicine published by Beijing Hospital and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Review Articles
Oliva, Anthony A.
McClain‐Moss, Lisa
Pena, Andrea
Drouillard, Amy
Hare, Joshua M.
Allogeneic mesenchymal stem cell therapy: A regenerative medicine approach to geroscience
title Allogeneic mesenchymal stem cell therapy: A regenerative medicine approach to geroscience
title_full Allogeneic mesenchymal stem cell therapy: A regenerative medicine approach to geroscience
title_fullStr Allogeneic mesenchymal stem cell therapy: A regenerative medicine approach to geroscience
title_full_unstemmed Allogeneic mesenchymal stem cell therapy: A regenerative medicine approach to geroscience
title_short Allogeneic mesenchymal stem cell therapy: A regenerative medicine approach to geroscience
title_sort allogeneic mesenchymal stem cell therapy: a regenerative medicine approach to geroscience
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820701/
https://www.ncbi.nlm.nih.gov/pubmed/31667462
http://dx.doi.org/10.1002/agm2.12079
work_keys_str_mv AT olivaanthonya allogeneicmesenchymalstemcelltherapyaregenerativemedicineapproachtogeroscience
AT mcclainmosslisa allogeneicmesenchymalstemcelltherapyaregenerativemedicineapproachtogeroscience
AT penaandrea allogeneicmesenchymalstemcelltherapyaregenerativemedicineapproachtogeroscience
AT drouillardamy allogeneicmesenchymalstemcelltherapyaregenerativemedicineapproachtogeroscience
AT harejoshuam allogeneicmesenchymalstemcelltherapyaregenerativemedicineapproachtogeroscience